Key result
Women with polycystic ovary syndrome had significantly decreased blood, urine, and saliva Maresin-1 levels and elevated malondialdehyde and C-reactive protein levels compared to healthy controls.
Why the study?
Maresin-1 plays a major role in inflammatory disorders, and inflammation may contribute to polycystic ovary syndrome and its metabolic associations, but blood, saliva, and urine levels had not been evaluated.
Are blood, saliva, and urine levels of Maresin-1 and malondialdehyde altered in patients with polycystic ovary syndrome compared to healthy controls?
Case-Control (n=60)
No
Are blood, saliva, and urine levels of Maresin-1 and malondialdehyde altered in patients with polycystic ovary syndrome compared to healthy controls?
p-value: p=<0.001
Decreased Maresin-1 and elevated malondialdehyde and CRP levels across blood, urine, and saliva may serve as useful biomarkers for polycystic ovary syndrome.
May support Maresin-1 and MDA/CRP as PCOS biomarkers; hypothesis-generating in case-control data, requires prospective validation.
Background: Maresin-1 (MaR1) plays a major role in many inflammatory disorders. Polycystic ovary syndrome (PCOS) aside from a hormonal disorder, an inflammation might also contribute to PCOS and its metabolic associations. Therefore, the purpose of this prospective study first time was to find out the blood, saliva and urine levels of MaR1 in PCOS patients and evaluate the correlations with other metabolic and hormonal parameters. Methods: Thirty PCOS patients and 30 matched healthy controls were enrolled to prospective case control study. Blood, urine and saliva samples were simultaneously collected from participants after overnight fasting. MaR1 levels in blood, urine and saliva samples were determined by enzyme-linked immunosorbent assay. Ferriman-Gallwey score, anthropometric, hormonal and some other metabolic parameters were also recorded. Regression analysis was preformed to find out the relationship between MaR1, C-reactive protein (CRP) and malondialdehyde (MDA), and hormonal and metabolic parameters. Results: Patients with PCOS compared with control women had higher MDA and CRP and decreased MaR1 levels. Blood, urine and saliva MDA and MaR1 levels were similar and indicated parallel decrease or increase in the PCOS and control groups. Furthermore, regression analysis indicated that blood CRP and MDA was positively associated with luteinizing hormone (LH) and fasting insulin (FI) in PCOS group (p < 0.05) while blood, urine and saliva MaR1 was negatively associated with CRP and MDA. Conclusions: Present results (MaR1, CRP and MDA together) in case of PCOS suggests that decreased MaR1 and elevated MDA and CRP levels in patients with PCOS and may be considered as a useful early biomarker (especially MaR1) in diagnosis of PCOS disease that has not been previously reported and regular monitoring of their levels could be helpful in clinical decisions.
No takes yet. Share an insight, caveat, or question.
Yavuz et al. (2022) conducted a case-control in Polycystic ovary syndrome (PCOS) (n=60). Polycystic ovary syndrome (PCOS) vs. Healthy matched controls was evaluated on Blood, urine, and saliva Maresin-1 (MaR1) levels (p=<0.001). Women with polycystic ovary syndrome had significantly decreased blood, urine, and saliva Maresin-1 levels and elevated malondialdehyde and C-reactive protein levels compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: